Phathom PharmaceuticalsNASDAQ: PHAT

Phathom Pharmaceuticals stock has significantly declined since 2021, despite securing FDA approval for Vonoprazan to treat H. pylori infection and GERD. The company faced delays in launching its products due to the presence of a cancer-causing agent in commercial batches, but eventually received full FDA approval. PHAT aims to target a substantial market opportunity with Vonoprazan, potentially leading to a share price rally and challenging a billion-dollar market cap valuation.

FLORHAM PARK, N.J., May 28, 2024 (GLOBE NEWSWIRE) --  Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in June:

The FDA has set a target action date of July 19, 2024, for expanded approval of Voquenza, which would target the larger Non-Erosive GERD patient population. The global market for GERD therapies is expected to be $3.4 billion by 2032. A soon-to-be-initiated phase 3 study in 2024 is going to explore the use of Voquenza with "As Needed" dosing to treat Non-Erosive GERD patients.

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript

Phathom Pharmaceuticals' stock is down 35% from its August highs and is now trading at $9. The company has two approved indications for its drug vonoprazan and an upcoming PDUFA. Phathom has a cash balance of $213mn and a cash runway of 8-9 quarters, making it an attractive investment opportunity.

FLORHAM PARK, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in November:

Phathom Pharmaceuticals is a small biopharma firm focused on developing treatments for gastrointestinal diseases. The company has recently filed some marketing applications around its primary drug candidate. The company ended the second quarter with just under $250 million in cash and marketable securities, and raised over $140 million via a secondary offering in front of launch activities.

Phathom Pharmaceuticals, Inc. is trading near 52-week highs. Despite its potential, there are reasons, like a competitive market, why we should take profits on Phathom Pharmaceuticals. If it falls back without major negative reasons before approval, we can always double down.

The mean of analysts' price targets for Phathom Pharmaceuticals, Inc. (PHAT) points to an 81.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.